Fiocruz Reasserts Partnership With AstraZeneca To Research Covid-19 Vaccine

On September 8th, it signed a technological order contract with AstraZeneca, which ensures access to 100.4 million doses of the active pharmaceutical ingredient for the vaccine's final processing, and also full technology transfer.

RIO DE JANEIRO, BRAZIL - After the University of Oxford announced on Saturday that it will resume trials of its Covid-19 vaccine, Fiocruz reasserted its partnership with Subscribe to our Premium Membership Plan. Already Subscribed?